These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34045311)

  • 1. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
    Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
    Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.
    Jalili P; Bowen D; Langenbucher A; Park S; Aguirre K; Corcoran RB; Fleischman AG; Lawrence MS; Zou L; Buisson R
    Nat Commun; 2020 Jun; 11(1):2971. PubMed ID: 32532990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
    Buisson R; Lawrence MS; Benes CH; Zou L
    Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 9. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Kong T; Ahn R; Yang K; Zhu X; Fu Z; Morin G; Bramley R; Cliffe NC; Xue Y; Kuasne H; Li Q; Jung S; Gonzalez AV; Camilleri-Broet S; Guiot MC; Park M; Ursini-Siegel J; Huang S
    Cancer Res; 2020 Feb; 80(3):444-457. PubMed ID: 31722999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
    Yang M; Li Z; Tao J; Hu H; Li Z; Zhang Z; Cheng F; Sun Y; Zhang Y; Yang J; Wei H; Wu Z
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1101-1113. PubMed ID: 33471184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
    Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
    Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms Controlling PD-L1 Expression in Cancer.
    Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
    Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.
    Hou J; Zhao R; Xia W; Chang CW; You Y; Hsu JM; Nie L; Chen Y; Wang YC; Liu C; Wang WJ; Wu Y; Ke B; Hsu JL; Huang K; Ye Z; Yang Y; Xia X; Li Y; Li CW; Shao B; Tainer JA; Hung MC
    Nat Cell Biol; 2020 Oct; 22(10):1264-1275. PubMed ID: 32929201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma.
    Yang Z; Wang J; Chen C; Sun P; Yu Y
    Technol Cancer Res Treat; 2021; 20():15330338211046432. PubMed ID: 34632870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF
    Feng D; Qin B; Pal K; Sun L; Dutta S; Dong H; Liu X; Mukhopadhyay D; Huang S; Sinicrope FA
    Oncogene; 2019 Oct; 38(41):6752-6766. PubMed ID: 31406255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
    Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.